Login to Your Account



Clinic Roundup


Tuesday, March 6, 2012
• Endocyte Inc., of West Lafayette, Ind., said the FDA approved its importation of a supply of Doxil (doxorubicin) from Europe for a Phase III trial (PROCEED). The trial began in May 2011, but the company stopped enrollment because of global shortages of Doxil. PROCEED compares EC145 in combination with Doxil to Doxil alone for ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription